论文部分内容阅读
本文采用免疫组化技术,从93年初开始前瞻性研究了乳腺癌雌孕激素受体测定,指导治疗及生物学意义。至94年底共检测175例乳腺癌,其中ER、PR阳性率分别为56.57％,69.71％。ER(+)PR(+)共92例,ER(-)PR(-)共46例,ER和PR表达一致率为78.86％。而ER(+)PR(-)7例,ER(-)PR(+)30例,可见有21.14％乳癌病例为ER或PR单项阳性表达。经统计学分析,ER、PR阳性率与病人年龄、月经状况、肿瘤大小、临床分期、淋巴结有无转移及病理组织类型无显著相关性。ER、PR测定意义在于指导临床选择治疗方案和判定预后。
In this article, immunohistochemical technique was used to prospectively study the estrogen and progesterone receptors in breast cancer from the beginning of the year 93, to guide the treatment and biological significance. By the end of 1994, a total of 175 cases of breast cancer were detected, of which the positive rates of ER and PR were 56.57% and 69.71%, respectively. There were 92 cases of ER(+)PR(+) and 46 cases of ER(-)PR(-). The consistent rate of ER and PR expression was 78.86%. There were 7 cases of ER(+)PR(-) and 30 cases of ER(-)PR(+). There was 21.14% of cases of breast cancer with positive expression of ER or PR. After statistical analysis, the positive rates of ER and PR were not significantly associated with the patient’s age, menstrual status, tumor size, clinical stage, lymph node metastasis, and pathological type. The significance of ER and PR measurement is to guide the clinical choice of treatment plan and determine the prognosis.